Format

Send to

Choose Destination
Int J Hematol. 2016 Jul;104(1):6-17. doi: 10.1007/s12185-016-2039-6. Epub 2016 Jun 4.

Biology and clinical application of CAR T cells for B cell malignancies.

Author information

1
Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA. marco.davila@moffitt.org.
2
Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Abstract

Chimeric antigen receptor (CAR)-modified T cells have generated broad interest in oncology following a series of dramatic clinical successes in patients with chemorefractory B cell malignancies. CAR therapy now appears to be on the cusp of regulatory approval as a cell-based immunotherapy. We review here the T cell biology and cell engineering research that led to the development of second generation CARs, the selection of CD19 as a CAR target, and the preclinical studies in animal models that laid the foundation for clinical trials targeting CD19+ malignancies. We further summarize the status of CD19 CAR clinical therapy for non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia, including their efficacy, toxicities (cytokine release syndrome, neurotoxicity and B cell aplasia) and current management in humans. We conclude with an overview of recent pre-clinical advances in CAR design that argues favorably for the advancement of CAR therapy to tackle other hematological malignancies as well as solid tumors.

KEYWORDS:

Adoptive T cell therapy; CD19; Chimeric antigen receptor; Immunotherapy; T cell engineering

PMID:
27262700
PMCID:
PMC5512169
DOI:
10.1007/s12185-016-2039-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center